866-997-4948(US-Canada Toll Free)

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 64 Pages

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2016, provides in depth analysis on Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
- The report reviews Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) Overview 7
Therapeutics Development 8
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Products under Development by Stage of Development 8
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Products under Development by Therapy Area 9
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Products under Development by Indication 10
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Products under Development by Companies 14
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Products under Development by Universities/Institutes 16
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Companies Involved in Therapeutics Development 25
ID Pharma Co., Ltd. 25
Kringle Pharma, Inc. 26
Momenta Pharmaceuticals, Inc. 27
Ohr Pharmaceutical Inc. 28
Ribomic Inc. 29
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Drug Profiles 30
Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
CT-400 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
CT-400P - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
DVC-10101 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
necuparanib - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
NK-4 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Protein to Activate FGF2 for Wound Healing - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
RBM-007 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Recombinant Protein to Inhibit FGF-2 for Cancer - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
squalamine lactate - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
TR-764 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Dormant Projects 49
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Discontinued Products 51
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Featured News & Press Releases 52
Aug 04, 2016: Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis 52
Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO 52
May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting 53
May 02, 2016: Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee 54
Apr 27, 2016: Ohr Pharmaceutical Announces Presentation on Squalamine Lactate at the 2016 Association for Research in Vision and Ophthalmology Conference in Seattle, WA 54
Apr 18, 2016: Ohr Pharmaceutical, Inc. Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program 55
Mar 29, 2016: Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program 55
Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 56
Nov 16, 2015: Ohr Pharmaceutical Presents New Data From OHR-102 Phase II IMPACT Study in Wet-AMD at American Academy of Ophthalmology Annual Meeting 57
Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 58
Nov 12, 2015: Ohr Pharmaceutical Announces Submission of a Special Protocol Assessment and Upcoming Presentation on OHR-102 at American Academy of Ophthalmology 58
Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion 59
Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer 60
May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting 61
May 07, 2015: Ohr Pharmaceutical Presents Data From OHR-102 Phase II IMPACT Study in Wet-AMD at ARVO Conference 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 24
Pipeline by ID Pharma Co., Ltd., H2 2016 25
Pipeline by Kringle Pharma, Inc., H2 2016 26
Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 27
Pipeline by Ohr Pharmaceutical Inc., H2 2016 28
Pipeline by Ribomic Inc., H2 2016 29
Dormant Projects, H2 2016 49
Dormant Projects (Contd..1), H2 2016 50
Discontinued Products, H2 2016 51

List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Mechanism of Actions, H2 2016 19
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Routes of Administration, H2 2016 21
Number of Products by Stage and Routes of Administration, H2 2016 21
Number of Products by Molecule Types, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *